This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CFO and Board Member Chris Buyse to Resign
LEUVEN, Belgium, June 24, 2014 (GLOBE NEWSWIRE) -- In response to market rumors, ThromboGenics NV (Euronext Brussels: THR) today issues an update on the Strategic Review process that was initiated in February 2014.
Following an assessment of various strategic options including a sale of the entire company, the Board of Directors of ThromboGenics has decided to continue as a stand-alone company, and to pursue discussions for a potential partnership for the commercialization of JETREA in the US. The Company will provide a further update at the time of its 2014 half year reporting on August 28.
Separately, Chris Buyse, Chief Financial Officer and Board Member of ThromboGenics, will resign effective June 30, 2014. Chris was appointed CFO of ThromboGenics following its 2006 IPO and has played an important role in building ThromboGenics.
As of July 1, Luc Philips, former CFO of KBC group and Board Member of ThromboGenics since its IPO, will take on the role of interim-CFO until the Company completes an international search for a new permanent CFO.
For further information please contact:
About JETREA® (ocriplasmin)
® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA
® is indicated for the treatment of symptomatic VMA. In Europe, JETREA
® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.